
|Videos|October 17, 2014
Combining Targeted Agents for the Treatment of Lung Cancer
Author(s)Heather Wakelee, MD
Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
Advertisement
Clinical Pearls
Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.
- It is widely believed that 1 molecularly-targeted agent will not be able to cure lung cancer.
- Long term responses have been observed with 1 targeted agent.
- Research needs to be conducted regarding which combinations of agents will be most beneficial or curative.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















